Title : (-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice - Grove_2012_Obesity.(Silver.Spring)_20_2311 |
Author(s) : Grove KA , Sae-tan S , Kennett MJ , Lambert JD |
Ref : Obesity (Silver Spring) , 20 :2311 , 2012 |
Abstract :
Tea (Camellia sinensis, Theaceae) has been shown to have obesity preventive effects in laboratory studies. We hypothesized that dietary epigallocatechin-3-gallate (EGCG) could reverse metabolic syndrome in high fat-fed obese C57bl/6J mice, and that these effects were related to inhibition of pancreatic lipase (PL). Following treatment with 0.32% EGCG for 6 weeks, a 44% decrease in body weight (BW) gain in high fat-fed, obese mice (P < 0.01) was observed compared to controls. EGCG treatment increased fecal lipid content by 29.4% (P < 0.05) compared to high fat-fed control, whereas in vitro, EGCG dose-dependently inhibited PL (IC(50) = 7.5 micromol/l) in a noncompetitive manner with respect to substrate concentration. (-)-Epicatechin-3-gallate exhibited similar inhibitory activity, whereas the nonester-containing (-)-epigallocatechin did not. In conclusion, EGCG supplementation reduced final BW and BW gain in obese mice, and some of these effects may be due to inhibition of PL by EGCG. |
PubMedSearch : Grove_2012_Obesity.(Silver.Spring)_20_2311 |
PubMedID: 21633405 |
Gene_locus related to this paper: human-PNLIP |
Inhibitor | Epicatechin-gallate Epigallocatechin-gallate |
Substrate | Epicatechin-gallate Epigallocatechin-gallate |
Gene_locus | human-PNLIP |
Grove KA, Sae-tan S, Kennett MJ, Lambert JD (2012)
(-)-Epigallocatechin-3-gallate inhibits pancreatic lipase and reduces body weight gain in high fat-fed obese mice
Obesity (Silver Spring)
20 :2311
Grove KA, Sae-tan S, Kennett MJ, Lambert JD (2012)
Obesity (Silver Spring)
20 :2311